Please assess the completion status of the following clinical trial:

Trial Title: LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Age 21 to 75 years, inclusive~2. Patient has a single target IA that: is located in the following regions of the internal carotid artery:~   1. Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments)~  2. Cavernous~  3. Petrous~3. has a parent vessel with diameter 2.5-5.0 mm~4. Wide neck aneurysm ≥4 mm.~5. Target IA has size (maximum fundus diameter) 10 mm~6. The operator feels that the aneurysm can be appropriately treated with traditional endovascular techniques (endovascular coil embolization with or without adjunctive devices or parent artery deconstruction) using endovascular coiling or flow diversion devices.~7. Modified Rankin Scale 0-3~8. Signed and dated informed consent~4.2 Exclusion criteria~1. More than one IA requiring treatment in the next 6 months~2. Subarachnoid hemorrhage in the past 60 days~3. Any intracranial hemorrhage in the last 42 days~4. Major surgery (requiring general anesthesia) in the last 42 days~5. Coils in place in the target IA~6. Unstable neurologic deficit (i.e., any rapidly worsening clinical condition in the last 30 days (defined by a change in mRS of 2 or more))~7. Known irreversible bleeding disorder~8. Platelet count \< 100 x 103 cells/mm3 or known platelet dysfunction~9. Clinically documented evidence in medical history of adverse reaction or contraindication to medications used in treatment of the aneurysm (i.e. Plavix, heparin, aspirin)~10. Prior stent placement at target site~11. Documented history of dementia~12. Contraindication to CT scan and MRI (ie. contrast allergy, or other condition that prohibits imaging from either CT or MRI)~13. Known allergy to contrast used in angiography that cannot be medically controlled~14. Known severe allergy to platinum or cobalt/chromium alloys~15. Relative contraindication to angiography (e.g., serum creatinine \> 2.5 mg/dL)~16. Pregnancy, breast-feeding, or positive pregnancy test \[either serum or urine\] (Woman of child-bearing potential must have a negative pregnancy test prior to the study procedure.)~17. Evidence of active infection (indicated by fever \[at or over 99.9 °F\] and/or open draining wound) at the time of randomization~18. Other known conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis)~19. Current use of cocaine or other illicit substance~20. Any comorbid disease or condition expected to compromise survival or ability to complete Follow-up assessments through 180 days~21. Extracranial stenosis greater than 50% in the carotid artery~22. Intracranial stenosis greater than 50% in the treated vessel~23. Based on investigator's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule.~24. Previously randomized into this trial or currently participating in another trial where the data is intended to be used to obtain marketing approval or to broaden an indication, without the approval of the study principal investigator, that may confound the results of this study.~A screen failure log of all cases referred or presented for possible inclusion, but who were not randomized, and the reason(s) for exclusion will be maintained.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Coiling (Type: ACTIVE_COMPARATOR): Coiling
- Flow Diversion (Type: ACTIVE_COMPARATOR): Flow Diversion

Based on this trial design, predict the completion outcome and termination type (if applicable).